Shares of PACS Group cratered 10.4% to $40.13 the day after the post-acute healthcare giant reported second-quarter results that, on paper, looked strong. The selloff, happening against an otherwise calm market, signals Wall Street is scrutinizing not just what PACS earned, but how cleanly it earned it — and what the growing acquisition machine means for per-share profitability.

• Revenue Grew, but Earnings Per Share Fell Short by a Wide Margin

Revenue hit $1.43 billion, up 9.1% year-over-year , and adjusted EBITDA reached $166.8 million, up 24.6%. But diluted EPS came in at $0.47, missing the consensus estimate of $0.53 — a 17% miss.

Analysts had expected $0.537 per share , so the gap was not trivial. When a company grows revenue and operating profit handsomely but still disappoints on the bottom line, investors immediately question where the money went — whether into acquisition costs, higher interest expense, or share dilution.

• Management Raised the Bar for 2026, but the Market Isn't Buying It Yet

PACS lifted full-year adjusted EBITDA guidance to $640–$660 million (from $605–$625 million) and revenue guidance to $5.75–$5.85 billion (from $5.65–$5.75 billion), representing roughly 29% growth over 2025. That's a significant raise. Yet the stock's plunge suggests investors worry this growth is being purchased through acquisitions — like the ongoing 34-facility Eduro deal — rather than flowing through to shareholders on a per-share basis.

• The Acquisition Appetite Is Back, and That Cuts Both Ways

PACS boasts $757 million in available cash and credit , and executives signaled more deals ahead beyond Eduro, with the CFO telling investors to expect additional facility closings before year-end. Aggressive dealmaking fuels top-line growth but carries integration risk. Same-store revenue — existing facilities, not new ones — grew a healthy 5.8%, with occupancy climbing 150 basis points to 90.6%. That organic engine is real, but it was overshadowed by the EPS miss.

• A Pattern of Post-Earnings Drops Raises the Stakes

PACS also fell roughly 12.5% after its Q4 2025 results , suggesting a recurring tension: management showcases operational momentum while bottom-line delivery underwhelms the Street's expectations. Until per-share earnings catch up to the headline growth story, every beat on revenue risks being read as proof that growth is dilutive — meaning it adds scale but not proportional profit for each share. That's the puzzle PACS must solve before the market will reward its ambitions.